Shares of Ultragenyx Pharmaceutical RARE rose in after-market trading after the company reported Q4 results.
Quarterly Results
Earnings per share rose 77.16% over the past year to ($0.37), which beat the estimate of ($1.16).
Revenue of $91,542,000 higher by 157.19% year over year, which beat the estimate of $70,540,000.
Looking Ahead
Ultragenyx Pharmaceutical hasn't issued any earnings guidance for the time being.
Ultragenyx Pharmaceutical hasn't issued any revenue guidance for the time being.
How To Listen To The Conference Call
Date: Feb 11, 2021
Time: 05:00 PM
ET Webcast URL: https://edge.media-server.com/mmc/p/gsc2oah6
Recent Stock Performance
Company's 52-week high was at $179.65
Company's 52-week low was at $31.99
Price action over last quarter: Up 71.35%
Company Description
Ultragenyx Pharmaceutical Inc is a US-based biopharmaceutical company. It identifies, acquires, develops, and commercialize novel products for the treatment of serious rare and ultra-rare diseases, with the focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
